Theraclone Gets Funding for HIV

Xconomy Seattle — 

Theraclone Sciences, the Seattle-based developer of antibody drugs formerly known as Spaltudaq, said today it has received additional funding from the International AIDS Vaccine Initiative to continue developing antibodies that could lead to an AIDS vaccine, or new treatment. The HIV virus has dodged past attempts to develop antibody-based treatments or vaccines, because it mutates quickly to avoid them, but Theraclone’s approach follows clues from the immune systems of people with rare immune systems that give them natural protection against the virus, as I described in this April feature. Financial terms weren’t disclosed.

By posting a comment, you agree to our terms and conditions.

2 responses to “Theraclone Gets Funding for HIV”

  1. keith says:

    A survey from CDC shows that there are more than people 550,000 joined the std dating site and the number are increasinb by hundreds everyday! What amazing!

  2. chloe says: — This is a warm-hearted and exclusive community for singles and friends with STDs. Here you can get on with your life and meet new friends, partners or potential spouses, or learn about STD medical information, or find someone to talk to or offer help and advice. Never feel lonely again!